Adjuvant chemotherapy ups survival in mucinous colon cancer

  • Fields AC & al.
  • J Surg Oncol
  • 19 sept. 2019

  • de Jim Kling
  • Univadis Clinical Summaries
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • Adjuvant chemotherapy is associated with better survival in stage II/III mucinous colon adenocarcinoma.

Why this matters

  • The prognosis and effect of adjuvant chemotherapy has not been clearly established in mucinous colon cancer, and this study is one of the largest to date.

Study design

  • Retrospective analysis of records from the National Cancer Database (n=31,041) with stage II/III mucinous colon adenocarcinoma.
  • Propensity-matched analysis: 3302 with stage II, 5564 with stage III.
  • Funding: None disclosed.

Key results

  • In adjusted analysis, there was no significant difference in survival between patients with stage II nonmucinous vs mucinous adenocarcinoma (HR, 0.99; P=.60).
  • Survival in stage III disease favored nonmucinous disease (HR, 1.05; P<.001>
  • Adjuvant chemotherapy was associated with better survival in mucinous adenocarcinoma:
    • Stage II: 5 years: 78.4% vs 73.7%; 10 years: 61.9% vs 54.3% (HR, 0.79; P.
    • Stage III: 5 years: 55.8% vs 36.8%; 10 years: 33.7% vs 19.2% (HR, 0.56; P

Limitations

  • Retrospective.
  • Limited information on specific chemotherapy regimens, adverse events.